---
title: "Descartes-08 in Generalized myasthenia gravis: Dosage forms and strengths"
description: "Formulary evidence on Descartes-08 in Generalized myasthenia gravis: Dosage forms and strengths. Topics: Target dose per infusion from a single apheresis: phase 2b, Product supplied as frozen aliquots tested before release: phase 1b/2a, Matched placebo presentation in the phase 2b trial, and Patient-specific manufacture. 4 evidence topics quoted from 4 sources."
canonical: "https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/product-information-and-disease-description/dosage-forms-and-strengths"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Descartes-08 in Generalized myasthenia gravis: Dosage forms and strengths

<a id="heading-2.1.2.2"></a>

## 2.1.2.2 Dosage Forms and Strengths

<a id="topic-2.1.2.2-1"></a>

### Target dose per infusion from a single apheresis: phase 2b

> “A single apheresis was sufficient to reach the target dose of 52.5 × 10⁶ viable CAR+ cells per kilogram ± 45% for each of six once-weekly infusions.”

Source: [Fedak et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13004674/)

<a id="topic-2.1.2.2-2"></a>

### Product supplied as frozen aliquots tested before release: phase 1b/2a

> “The autologous product was divided into multiple aliquots, frozen, and tested for sterility, cell quality, CAR expression, and potency.”

Source: [Granit et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10416207/)

<a id="topic-2.1.2.2-3"></a>

### Matched placebo presentation in the phase 2b trial

> “The placebo was matched to Descartes-08 in appearance and supplied in identical containers.”

Source: [Vu et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13004676/)

<a id="topic-2.1.2.2-4"></a>

### Patient-specific manufacture

> “Our autologous cell therapy product candidates, including Descartes-08, are manufactured on a patient-by-patient basis.”

Source: [Cartesian Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1453687/000145368726000064/rnac-20251231.htm)

## Related pages
- [Descartes-08: Generalized myasthenia gravis](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis.md)
- [Descartes-08 in Generalized myasthenia gravis: Terms and abbreviations](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/terms-and-abbreviations.md)
- [Descartes-08: Generalized myasthenia gravis](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/executive-summary.md)
- [Descartes-08 in Generalized myasthenia gravis: Product information and disease description](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/product-information-and-disease-description.md)
- [Descartes-08 in Generalized myasthenia gravis: Clinical evidence](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/clinical-evidence.md)
- [Descartes-08 in Generalized myasthenia gravis: Economic information and modeling report](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/economics) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/economics.md)
- [Descartes-08 in Generalized myasthenia gravis: References](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/references) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/references.md)
